PubRank

Adrián Alegre

Author PubWeight™ 20.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011 2.58
2 Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012 2.42
3 Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008 1.43
4 [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]. Med Clin (Barc) 2009 1.40
5 Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007 1.29
6 Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007 1.06
7 Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002 0.96
8 Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005 0.93
9 Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002 0.91
10 Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica 2008 0.88
11 Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003 0.87
12 Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006 0.84
13 Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 2011 0.84
14 Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009 0.83
15 Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008 0.82
16 Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 2011 0.80
17 Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Curr Med Res Opin 2011 0.79
18 Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields. J Hematother Stem Cell Res 2002 0.78
19 Clonal evolution in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010 0.76
20 Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patient. Br J Haematol 2002 0.75